Elderly and PS 2 Patients With Advanced NSCLC Winter Lung Cancer Conference 2012

Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw,

unedited content. Select slides from the original presentation are omitted where Research To

Practice was unable to obtain permission from the publication source and/or author. Links to view the actual reference materials have been provided for

your use in place of any omitted slides.

Elderly and PS 2 Patients With Advanced NSCLC

Winter Lung Cancer Conference2012

Rogerio Lilenbaum, MD, FACPCleveland Clinic Florida

Weston, FL


• Combination vs. Single Agent Therapy

• Bevacizumab with chemotherapy

• Targeted agents in unselected patients

IFCT Study Schema

*Choice of the center at the beginning of the study; ** In case of PD or excessive toxicity

NSCLCStage III-IVAge 70-89

yearsPS 0-2 n = 451

Vinorelbine or

Gemcitabine*

Carboplatin + paclitaxel

Erlotinib**150 mg/d

RANDOM

Stratification by center, PS 0-1 vs. 2, age ≤80 vs. >80 and stage III vs. IV

Ref: Quoix E, Zalcman G, Oster JP, et al; Intergroupe Francophone de Cancérologie Thoracique. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011 Sep 17;378(9796):1079-88.

PFS (ITT) Quoix et al

• Doublet chemotherapy

• Median PFS: 6.1 months (95% CI 5.5-6.9)

• 1-year PFS: 15.4% (95% CI 10.8-20.8)

• Monotherapy

• Median PFS: 3.0 months (95% CI 2.6-3.9)

• 1-year PFS: 2.3% (95% CI 0.8-5.3)

• p < 10-6

Overall survival (ITT) Quoix et al

• Doublet chemotherapy

• MST = 10.3 months (95% CI 8.3-13.3)

• 1-year survival 45.1% (95% CI 38.2-51.8)

• Monotherapy

• MST = 6.2 months (95% CI 5.3-7.4)

• 1-year survival 26.9% (95% CI 21-33.1)

• p = 0.00004

Exploratory Sub-group analysis

"Despite increased toxic effects, platinum-based doublet chemotherapy was associated with survival benefits compared with vinorelbine or gemcitabine monotherapy in elderly patients with NSCLC."

Brazilian PS2 NSCLC: Trial Design

Chemotherapy-naivepatients with stage IIIB (with pleural effusion)

or IV NSCLC and ECOG PS 2

N= 208

RANDOMIZE

Pemetrexed 500 mg/m2 IV q 21 days(max 4 cycles)

Carboplatin AUC=5 IV q 21 days Pemetrexed 500 mg/m2 IV q 21 days(max 4 cycles)

Primary Objective: OS

Trial closed – submitted to ASCO 2012


• Combination vs. Single Agent Therapy– Elderly: Yes– PS 2: TBD







Outcomes for Elderly Advanced NSCLC Patients Treated with Bevacizumab in Combination with Carboplatin and Paclitaxel:

Analysis of ECOG 4599 Study

Elderly (≥ 70)* Non-Elderly (< 70)PC PCB PC PCB

CR+PR 17% 29% 14% 36%

SD 50% 39% 50% 39%Median

PFS 4.9 m 5.9 mP=0.063 4.4 m 6.2 m

P<0.0011-Yr

Survival 50% 46% 42% 53%

Median survival 12.1 m 11.3 m

P = 0.4 9.6 m 12.8 mP = 0.0027

Ramalingan et al. JCO 2008

*Median Age “Elderly”: 74

Toxicity on PCB Arm: Elderly vs. Non-Elderly

Grade 3/4 > 70 yrs < 70 yrs PNeutropenia (Gr 4) 34% 22% 0.02Melena/GI Bleed 3.5% 0.9% 0.005

Proteinuria 7.9% 1.3% 0.001Motor neuropathy 3.5% 0.6% 0.05Worst Grade 87% 70% < 0.001TRDs 6.3% 2.6% 0.08

Outcomes for Elderly Patients Treated With Bevacizumab in Combination with Cisplatin and

Gemcitabine: Analysis of the AVAIL Study

CGN=112

CGB – 7.5

N=89

CGB – 15

N=103

CGN-235

CGB – 7.5

N=256

CGB – 15

N=248ORR 30% 40% 29% 24% 41% 44%PFS 0.71 0.84 0.76 0.85OS 0.84 0.88 0.98 1.09

Leighl et al. JCO 2008

*Median Age Elderly Group: 68 (36% 70 or older)

Elderly Group ≥ 65* Younger Group < 65

Results reported in HR

Elderly Patients : Toxicity Analysis of the AVAIL Study

Only Gr≥3 PLT more frequent with Bev . Post Hoc analysis of ≥ 70 vs. 70 similar to age 65 cutoff

Bev in PS 2 Advanced NSCLC: TOPPS

Chemotherapy-naivepatients with stage IIIB (with pleural effusion)

or IV NSCLC and ECOG PS 2

RANDOMIZE

Pemetrexed 500 mg/m2 IV q 21 days

Carboplatin AUC=5 IV q 21 days Pemetrexed 500 mg/m2 IV q 21 daysBevacizumab 15 mg/kg IV q 21 days

Primary Objective: PFS Secondary Objectives:ORRToxicityOS

Pemetrexed 500 mg/m2 IV q 21 daysBevacizumab 15 mg/kg IV q 21 days



• Bevacizumab with chemotherapy– Age alone is not a contraindication to Bev– Exercise caution with very old patients and/or those with

significant co-morbidities or compromised PS






Erlotinib or Chemotherapy in PS2 Patients

Arm E = 52 CP = 51OOR (%) 4 12SD (%) 37 43PD (%) 44 20PFS (mo) 1.9 3.5MST (mo) 6.6 9.51y OS (%) 21 45

Lilenbaum et al. JCO 2008

TOPICAL

Erlotinib*(150mg/day)

to PD

Placebo*to PD

1:1 randomization

Inclusion criteria• Histologically/cytologically

confirmed NSCLC

• Measurable stage IIIB/IV disease and ≥ 18 yrs

• Chemo-naive and unsuitable for chemotherapy:– ECOG PS 2–3 or– PS 0–1 with impaired renal function CC<60ml/min

• Life expectancy ≥8 weeks

Primary• Overall survival (OS)

Secondary• Progression-free survival

(PFS)

• Objective response rate• Quality of life (QoL)• Disease-related

symptoms • Safety and tolerability

Translational• Biomarker analyses

– EGFR mutation– proteomic/genomic

markers

Endpoints

*+/- palliative XRT

Lee SM et al ASCO 2010

Erlotinib (n=350)

Placebo (n=320)

Age, median (range), years 77.4 (42–91) 77.2 (45–91)

Male / female, % 61 / 39 61 / 39

Stage IIIB / IV, % 36 / 64 33 / 67

ECOG PS 0–1 / 2 / 3, % 16 / 55 / 29 16 / 56 / 28

Adeno / squamous cell / large cell / other, % 38 / 38 / 4 / 20 38 / 40 / 5 / 17

Caucasian / Asian / other, % 96 / 2 / 2 98 / 1 / 1

Current / ex- / never smoker, % 36 / 59 / 5 37 / 57 / 6

Pack-years (current/ex-smoker), median (range) 40 (1–220) 38 (1–130)

Median time since cessation (ex-smoker), years 18 17

Baseline characteristics

*Asian = East, Southeast, South Asia; other = African-Caribbean

TOPICAL Trial

Arm E = 350 P = 320PFS (m) 2.8 mo 2.7 moPFS (6mo) 22% 13%PFS (1y) 9% 4%OS (m) 3.8 mo 3.6 moOS (6mo) 36% 33%OS (1y) 16% 14%

Lee et al. ASCO 2010

OS: planned subgroups

• Overall, erlotinib plus BSC did not improve OS

• Clear effect on OS for females




• Targeted agents in unselected patients– First-line use of TKIs should be based on molecular

selection– Consider erlotinib in female patients with

adenocarcinoma, if the alternative is no therapy

Saturday, February 11, 2012Hollywood, Florida

Faculty

Co-ChairsRogerio C Lilenbaum, MDMark A Socinski, MD

Co-Chair and ModeratorNeil Love, MD

Chandra P Belani, MDJohn Heymach, MD, PhDPasi A Jänne, MD, PhD

Thomas J Lynch Jr, MDHeather Wakelee, MD

Documents

Elderly and PS 2 Patients With Advanced NSCLC Winter Lung Cancer Conference 2012